Cargando…
First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial
Autor principal: | Kumaraswamy, Santosh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388336/ https://www.ncbi.nlm.nih.gov/pubmed/34465967 http://dx.doi.org/10.4103/iju.IJU_534_20 |
Ejemplares similares
-
Nectin-4 inhibitors: An ace up our sleeve against advanced urothelial carcinoma
por: Kumaraswamy, Santosh
Publicado: (2021) -
Pharmacological prophylaxis for venous thromboembolism: Is it time to change the gold standard?
por: Kumaraswamy, Santosh
Publicado: (2021) -
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
por: Powles, Thomas, et al.
Publicado: (2023) -
POUT trial: Perioperative chemotherapy in upper tract urothelial carcinoma – A standard of care?
por: Ranjan, Satish Kumar
Publicado: (2020) -
What is the role of adjuvant chemotherapy in locally advanced and lymph node-positive bladder cancer after radical cystectomy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)